504 CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation
Chuan Wang(Qilu Hospital of Shandong University), Jianxin Yang(Ascepion Pharmaceuticals (China)), Jingyu Sun(Shanghai East Hospital), Ning Zhang(Ascepion Pharmaceuticals (China)), Xuelian Liu(Ascepion Pharmaceuticals (China)), Yongli Yang(Southwest Forestry University), Xinling Zhang(Qingdao University), Yongwang Li(Shenzhen Third People’s Hospital), Fei Ma(Ascepion Pharmaceuticals (China)), Mengyao Zhu(Ascepion Pharmaceuticals (China))
Cited by 0
Related Papers
Design and Mechanisms of Asymmetric Supercapacitors
|Chemical Reviews|2018|3.6k
Crafting Mussel‐Inspired Metal Nanoparticle‐Decorated Ultrathin Graphitic Carbon Nitride for the Degradation of Chemical Pollutants and Production of Chemical Resources
|Advanced Materials|2019|422
Bridging the Gap between Reality and Ideal in Chemical Vapor Deposition Growth of Graphene
|Chemical Reviews|2018|396
Towards super-clean graphene
|Nature Communications|2019|217